04.22.25 -- Is Your CGT Program Future-Proof?

Consider the benefits of advanced AAV production platforms, such as enhanced efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.

Choosing the right clinical packaging and supply chain partner to support APAC studies can vary significantly based upon which countries are involved and the types of services required.

Uncover guiding principles to ensure that your CGT supply chain is future-proof and learn how an agile, flexible approach can help advance your project with reduced costs and delays.

Few life sciences companies are ready for a disaster, particularly a cyber one. Key factors include an integrated approach to cyber preparedness and risk planning, a dedicated team, and more.

Explore the importance of adopting a Quality by Design (QbD) approach in the development process while integrating regulatory and CMC strategies for maximum efficiency and benefit.

By refining variables such as starting DNA, reagents, cell density, and media composition, organizations can improve rAAV process efficiency and scalability.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

In this study, we present a comprehensive analysis of various published and newly developed dsDNA conversion processes that were tested using the same sequencing chemistry.

See how quantitative mass spectrometry imaging (QMSI) and leading spatial bioanalysis and biology services can offer one-on-one support throughout your drug development process.

Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches.

Our comprehensive Adenovirus Vector Lot Release Package ensures the quality and safety of Adenovirus Vector lots through a series of rigorous assays and tests.

Cut costs, save time, reduce downtime, find support, maintain an overview — HERMA Connected Solutions, unique in the industry, offer powerful benefits.

Our state-of-the-art cryopreservation process, integrated with our end-to-end global temperature-controlled supply chain platform, provides unmatched reliability, efficiency, and scope.

By focusing on precision and quality, we aim to ensure that every therapeutic product meets the highest safety benchmarks, ultimately contributing to more successful treatments for patients in need.

Learn how a CDMO with 40+ years of GMP experience can help you overcome manufacturing challenges with the resources, the facilities, and the right people to support your project.